TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors

Recruiting Phase 3 Interventional Study
Ovarian Sex Cord Stromal Tumor Ovarian Neoplasms Ovarian Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
14 – 65
Sex
Female
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
132 (estimated)
Sponsor
Beihua Kong · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed ovarian malignant sex cord-stromal tumor patients after surgery.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age≤65 years; female, Chinese women; * Histologically confirmed ovarian stromal tumor, including the following cell types: * Granulosa cell tumor * Granulosa cell-theca cell tumor * Sertoli-Leydig cell tumor (androblastoma) * Steroid (lipid) cell tumor * Gynandrobla…
Contacts

Beihua Kong, MD. PhD.

+8618560081888

kongbeihua@sdu.edu.cn

CONTACT